{"id":10886,"date":"2023-10-30T10:45:12","date_gmt":"2023-10-30T10:45:12","guid":{"rendered":"https:\/\/www.thervacb.eu\/?p=10886"},"modified":"2023-11-03T15:13:51","modified_gmt":"2023-11-03T15:13:51","slug":"m4-award-2023","status":"publish","type":"post","link":"https:\/\/www.thervacb.eu\/fr\/m4-award-2023\/","title":{"rendered":"Bavarian Award \u2018m4\u2019 honours the TherVacB innovative therapeutic vaccine as a promising solution to the global health challenge of chronic hepatitis B"},"content":{"rendered":"

[et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.16″ da_disable_devices=\u00a0\u00bboff|off|off\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb da_is_popup=\u00a0\u00bboff\u00a0\u00bb da_exit_intent=\u00a0\u00bboff\u00a0\u00bb da_has_close=\u00a0\u00bbon\u00a0\u00bb da_alt_close=\u00a0\u00bboff\u00a0\u00bb da_dark_close=\u00a0\u00bboff\u00a0\u00bb da_not_modal=\u00a0\u00bbon\u00a0\u00bb da_is_singular=\u00a0\u00bboff\u00a0\u00bb da_with_loader=\u00a0\u00bboff\u00a0\u00bb da_has_shadow=\u00a0\u00bbon\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.16″ background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.16″ custom_padding=\u00a0\u00bb|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_padding__hover=\u00a0\u00bb|||\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.21.0″ background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Professor Ulrike Protzer and her TherVacB team at Helmholtz Munich and TUM have been honoured with the prestigious Bavarian m4 Award 2023. Key members of the Helmholtz Munich and TUM team for TherVacB proudly received the m4 Award on 24 October 2023 at Munich Residence (surrounded by BioM<\/sup> representatives on the picture are from left to right Dr. Anna Kosinska, Dr. Marian Wiegand, Prof. Dr. Ulrike Protzer, Romina Bester, Dr. Frank Thiele, Prof. Dr. Percy Knolle).<\/p>\n

The prize acknowledges their promising therapeutic hepatitis B vaccine that is able to reactivate antiviral immune responses. Preclinical models have already demonstrated its effectiveness in curing chronic infection, initial clinical trials will start soon. This includes a first-in-human study in healthy individuals<\/a> without HBV infection or hepatitis B immunization. Together with the TherVacB project team<\/a>, Ulrike Protzer\u2019s \u00a0ground-breaking research initiative will take the developed TherVacB vaccine to the next level in a clinical trial involving hepatitis B patients<\/a>.\u00a0\u00a0<\/p>\n

<\/h3>\n

[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbTurquoise box\u00a0\u00bb module_class=\u00a0\u00bbwhitelink\u00a0\u00bb _builder_version=\u00a0\u00bb4.21.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_2_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_3_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_4_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb background_color=\u00a0\u00bb#ce2525″ custom_padding=\u00a0\u00bb30px|30px|30px|30px|true|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Support for establishment of new therapeutic hepatitis B vaccine for HBV cure\u00a0
<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.21.0″ background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

For those suffering from chronic hepatitis B, no curative treatment option exists until today. Prof. Ulrike Protzer supported by the entire TherVacB team is on a mission to establish such a therapeutic hepatitis B vaccine for an HBV cure in routine clinical use.<\/p>\n

To this end, the m4 Award and prize money of 500,000 Euros will play a vital role. It facilitates the essential development steps required for the ultimate formulation of the TherVacB vaccine after initial clinical trial results. Importantly, it supports preparations for the establishment of a spin-off company to drive further clinical development to finally make the TherVacB therapy broadly available to hepatitis B patients<\/a>.<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbTurquoise box\u00a0\u00bb module_class=\u00a0\u00bbwhitelink\u00a0\u00bb _builder_version=\u00a0\u00bb4.21.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_2_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_3_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_4_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb background_color=\u00a0\u00bb#ce2525″ custom_padding=\u00a0\u00bb30px|30px|30px|30px|true|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

About the Bavarian m4 Award <\/strong><\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.21.0″ background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

The Bavarian Ministry of Economic Affairs<\/a> and BioM<\/sup><\/a> grant the m4 Award biennially to innovative academic research projects with spin-off potential in the field of biomedicine. <\/span>The Munich Biotechnology Cluster BioM<\/sup> drives Bavarian Biotech Cluster Development by supporting biotech companies from the German Federal State of Bavaria at every stage of setting up their business.\u00a0<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_cta title=\u00a0\u00bbFollow our journeys\u00a0\u00bb _builder_version=\u00a0\u00bb4.21.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#706F6F\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Watch BioM<\/sup>‘s summary video about TherVacB<\/a>\u00a0 and read the Press Release<\/a> to learn more about Ulrike Protzer’s team at Helmholtz Munich and TUM.\u00a0
<\/span><\/span><\/p>\n

Stay tuned on Twitter at @TherVacB_EU<\/a> and @protzerlab.\u00a0 <\/span>
<\/span><\/p>\n

[\/et_pb_cta][et_pb_text admin_label=\u00a0\u00bbTurquoise box\u00a0\u00bb module_class=\u00a0\u00bbwhitelink\u00a0\u00bb _builder_version=\u00a0\u00bb4.21.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_2_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_3_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_4_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb background_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb custom_padding=\u00a0\u00bb30px|30px|30px|30px|true|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Professor Ulrike Protzer and her TherVacB team at Helmholtz Munich and TUM have been honoured with the prestigious Bavarian m4 Award 2023. Key members of the Helmholtz Munich and TUM team for TherVacB proudly received the m4 Award on 24 October 2023 at Munich Residence (surrounded by BioM representatives on the picture are from left […]<\/p>\n","protected":false},"author":4,"featured_media":10896,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"

Experts in virology, immunology and clinical hepatitis from \u2018IP-cure-B \u2013 Take care of your health\u2019 and \u2018TherVacB - A therapeutic vaccine to cure Hepatitis B\u2019 research projects are working towards to cure hepatitis B.<\/h3>

To jointly tackle some of the major challenges in the therapy of viral hepatitis, researchers have met for a first round of strategic discussions in July 2023.<\/p>

Common goal to improve the cure rate of HBV and CHB <\/strong><\/h3>

To achieve functional cure, the research projects investigate different aspects of viral hepatitis B infection (HBV) and the HBV-mediated chronic disease.<\/p>

IP-cure-B aims to improve the cure rate in patients with chronic hepatitis B (CHB) with complementary immunomodulatory concepts. Immune interventions are investigated in two settings, in a pre-clinical model and a proof-of-concept clinical study. IP-cure-B innovations in immunotherapy will boost strategic selection of the best combination for effective treatment in future clinical studies.<\/p>

TherVacB provides a novel curative treatment option that aims to break immune tolerance in chronic HBV infection and allow the immune system to clear the virus. Novel TherVacB vaccine components will be tested in patients with CHB in a multicentre clinical proof-of-concept study. Finally, TherVacB aims to provide a novel and affordable, safe and well tolerable curative treatment option for CHB and a first opportunity for patients in Tanzania to be treated for hepatitis B.<\/p>

Contribute to the UN\u2019s Strategic Development Goals for sustained health in endemic countries<\/strong><\/h3>

The innovations from IP-cure-B and TherVacB will be instrumental to meeting the UN\u2019s Sustainable Development Goal 3:<\/p>

  • combat hepatitis B (and D) viral infection worldwide by the year 2023,<\/li>
  • ensure sustained health, increase the quality of life and stop stigmatization<\/li>
  • including in highly endemic countries that cannot afford lifelong therapies and their monitoring.<\/li><\/ul>

    \u00a0<\/p>

    TherVacB and IP-cure-B research projects have received funding from the EU's H2020 RIA programme (GA no. 848223 and 847939). Learn more on the European Commission\u2019s regularly updated Project Pages for TherVacB and IP-cure-B. Follow the journeys of IP-cure-B on Twitter @ipcureb and of TherVacB on Twitter @TherVacB_EU.<\/p>

    \u00a0<\/p>

    \u00a0<\/p>

    \u00a0<\/p>","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[58,16,1,18,13,17,15,14],"tags":[],"class_list":["post-10886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-nachrichten","category-news","category-noticias","category-noticies","category-notizia","category-nouvelles","category-14"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/posts\/10886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/comments?post=10886"}],"version-history":[{"count":9,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/posts\/10886\/revisions"}],"predecessor-version":[{"id":10912,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/posts\/10886\/revisions\/10912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/media\/10896"}],"wp:attachment":[{"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/media?parent=10886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/categories?post=10886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thervacb.eu\/fr\/wp-json\/wp\/v2\/tags?post=10886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}